IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

NASDAQ:ISO

IsoPlexis Corporation

Last Close

0.76

20/03 20:00

Market Cap

30.28M

Beta: -

Volume Today

111.02K

Avg: 47.29K

PE Ratio

−0.27

PFCF: −0.29

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics